Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties with a Hold Rating
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
The Motley Fool20d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
BOSTON, January 12, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s ...
The Motley Fool24d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.